Hepatorenal syndrome: A critical update

Seminars in Respiratory and Critical Care Medicine

Volumn 33, Issue 1, 2012, Pages 55-69

  Wadei, Hani M ^a  

^a MAYO CLINIC   (United States)

Author keywords

acute kidney injury; hepatorenal syndrome; liver cirrhosis; liver transplantation; vasopressin analogues

Indexed keywords

ALBUMIN; CEFTRIAXONE; CREATININE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FUROSEMIDE; INTERLEUKIN 18; MIDODRINE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; NORADRENALIN; NORFLOXACIN; OCTREOTIDE; PENTOXIFYLLINE; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PROSTAGLANDIN; TERLIPRESSIN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ACUTE KIDNEY FAILURE; ADRENAL INSUFFICIENCY; ADRENERGIC SYSTEM; ALBUMIN DIALYSIS; ALCOHOL LIVER DISEASE; ARTICLE; AUTOREGULATION; BACTERIAL PERITONITIS; BACTERIAL TRANSLOCATION; CONTINUOUS HEMOFILTRATION; CONTINUOUS INFUSION; CONTINUOUS RENAL REPLACEMENT THERAPY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE ASSOCIATION; DRUG DOSE TITRATION; FLUID RESUSCITATION; HEPATORENAL SYNDROME; HUMAN; HYPERKALEMIA; INTENSIVE CARE UNIT; INTERNATIONAL NORMALIZED RATIO; ISCHEMIA; KIDNEY BLOOD FLOW; KIDNEY PERFUSION; KIDNEY TRANSPLANTATION; LIFE EXPECTANCY; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; METABOLIC ACIDOSIS; MORTALITY; MULTIPLE ORGAN FAILURE; NATRIURESIS; PARACENTESIS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RENAL REPLACEMENT THERAPY; SIGNAL TRANSDUCTION; SURVIVAL; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; VASCULAR RESISTANCE; VASODILATATION;

HEPATORENAL SYNDROME; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; PREVALENCE; RENAL REPLACEMENT THERAPY; VASOCONSTRICTOR AGENTS;

EID: 84858739019     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0032-1301735     Document Type: Article

References (155)

1. Kastelan S, Ljubicic N, Kastelan Z, Ostojic R, Uravic M. The role of duplex-Doppler ultrasonography in the diagnosis of renal dysfunction and hepatorenal syndrome in patients with liver cirrhosis. Hepatogastroenterology: 2004; 51 59 1408 1412 (Pubitemid 38987494)
2. Platt JF, Ellis JH, Rubin JM, Merion RM, Lucey MR. Renal duplex Doppler ultrasonography: a noninvasive predictor of kidney dysfunction and hepatorenal failure in liver disease. Hepatology: 1994; 20 2 362 369 (Pubitemid 24233362)
3. Epstein M, Berk DP, Hollenberg NK., et al. Renal failure in the patient with cirrhosis: the role of active vasoconstriction. Am J Med: 1970; 49 2 175 185
4. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rods J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology: 1988; 8 5 1151 1157
5. Martin PY, Gins P, Schrier RW. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med: 1998; 339 8 533 541 (Pubitemid 28384887)
6. Mitchell JA, Kohlhaas KL, Sorrentino R, Warner TD, Murad F, Vane JR. Induction by endotoxin of nitric oxide synthase in the rat mesentery: lack of effect on action of vasoconstrictors. Br J Pharmacol: 1993; 109 1 265 270 (Pubitemid 23113832)
7. Laffi G, Foschi M, Masini E., et al. Increased production of nitric oxide by neutrophils and monocytes from cirrhotic patients with ascites and hyperdynamic circulation. Hepatology: 1995; 22 6 1666 1673
8. Bendtsen F, Schifter S, Henriksen JH. Increased circulating calcitonin gene-related peptide (CGRP) in cirrhosis. J Hepatol: 1991; 12 1 118 123
9. Guevara M, Gins P, Jimnez W., et al. Increased adrenomedullin levels in cirrhosis: relationship with hemodynamic abnormalities and vasoconstrictor systems. Gastroenterology: 1998; 114 2 336 343 (Pubitemid 28093542)
10. Fernndez-Rodriguez CM, Prieto J, Quiroga J., et al. Plasma levels of substance P in liver cirrhosis: relationship to the activation of vasopressor systems and urinary sodium excretion. Hepatology: 1995; 21 1 35 40
11. De las Heras D, Fernndez J, Gins P., et al. Increased carbon monoxide production in patients with cirrhosis with and without spontaneous bacterial peritonitis. Hepatology: 2003; 38 2 452 459 (Pubitemid 36919867)
12. Caraceni P, Viola A, Piscitelli F., et al. Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis. Liver Int: 2010; 30 6 816 825
13. Francs R, Zapater P, Gonzlez-Navajas JM., et al. Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis. Hepatology: 2008; 47 3 978 985 (Pubitemid 351449689)
14. Fernndez M, Semela D, Bruix J, Colle I, Pinzani M, Bosch J. Angiogenesis in liver disease. J Hepatol: 2009; 50 3 604 620
15. Paternostro C, David E, Novo E, Parola M. Hypoxia, angiogenesis and liver fibrogenesis in the progression of chronic liver diseases. World J Gastroenterol: 2010; 16 3 281 288
16. Mller S, Hobolth L, Winkler C, Bendtsen F, Christensen E. Determinants of the hyperdynamic circulation and central hypovolaemia in cirrhosis. Gut: 2011; 60 9 1254 1259
17. Kiszka-Kanowitz M, Henriksen JH, Mller S, Bendtsen F. Blood volume distribution in patients with cirrhosis: aspects of the dual-head gamma-camera technique. J Hepatol: 2001; 35 5 605 612 (Pubitemid 33078270)
18. Fernandez-Seara J, Prieto J, Quiroga J., et al. Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure. Gastroenterology: 1989; 97 5 1304 1312 (Pubitemid 19258718)
19. Maroto A, Gins P, Arroyo V., et al. Brachial and femoral artery blood flow in cirrhosis: relationship to kidney dysfunction. Hepatology: 1993; 17 5 788 793 (Pubitemid 23150086)
20. Guevara M, Bru C, Gins P., et al. Increased cerebrovascular resistance in cirrhotic patients with ascites. Hepatology: 1998; 28 1 39 44 (Pubitemid 28299983)
21. Helmy A, Newby DE, Jalan R, Johnston NR, Hayes PC, Webb DJ. Nitric oxide mediates the reduced vasoconstrictor response to angiotensin II in patients with preascitic cirrhosis. J Hepatol: 2003; 38 1 44 50 (Pubitemid 36078523)
22. Govindarajan S, Nast CC, Smith WL, Koyle MA, Daskalopoulos G, Zipser RD. Immunohistochemical distribution of renal prostaglandin endoperoxide synthase and prostacyclin synthase: diminished endoperoxide synthase in the hepatorenal syndrome. Hepatology: 1987; 7 4 654 659 (Pubitemid 17130706)
23. Navasa M, Follo A, Filella X., et al. Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality. Hepatology: 1998; 27 5 1227 1232 (Pubitemid 28227848)
24. Boyer TD, Zia P, Reynolds TB. Effect of indomethacin and prostaglandin A1 on renal function and plasma renin activity in alcoholic liver disease. Gastroenterology: 1979; 77 2 215 222 (Pubitemid 9206030)
25. Kostreva DR, Castaner A, Kampine JP. Reflex effects of hepatic baroreceptors on renal and cardiac sympathetic nerve activity. Am J Physiol: 1980; 238 5 R390 R394
26. Wong F, Sniderman K, Liu P, Allidina Y, Sherman M, Blendis L. Transjugular intrahepatic portosystemic stent shunt: effects on hemodynamics and sodium homeostasis in cirrhosis and refractory ascites. Ann Intern Med: 1995; 122 11 816 822
27. Jalan R, Forrest EH, Redhead DN, Dillon JF, Hayes PC. Reduction in renal blood flow following acute increase in the portal pressure: evidence for the existence of a hepatorenal reflex in man? Gut: 1997; 40 5 664 670 (Pubitemid 27278337)
28. Solis-Herruzo JA, Duran A, Favela V., et al. Effects of lumbar sympathetic block on kidney function in cirrhotic patients with hepatorenal syndrome. J Hepatol: 1987; 5 2 167 173 (Pubitemid 17144750)
29. Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology: 2006; 43 2, Suppl 1 S121 S131
30. Trevisani F, Sica G, Mainqu P., et al. Autonomic dysfunction and hyperdynamic circulation in cirrhosis with ascites. Hepatology: 1999; 30 6 1387 1392
31. Laffi G, Barletta G, La Villa G., et al. Altered cardiovascular responsiveness to active tilting in nonalcoholic cirrhosis. Gastroenterology: 1997; 113 3 891 898 (Pubitemid 27381149)
32. Ruiz-del-Arbol L, Urman J, Fernndez J., et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology: 2003; 38 5 1210 1218 (Pubitemid 37314829)
33. Ruiz-del-Arbol L, Monescillo A, Arocena C., et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology: 2005; 42 2 439 447 (Pubitemid 41061097)
34. Krag A, Bendtsen F, Henriksen JH, Mller S. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut: 2010; 59 1 105 110
35. Ripoll C, Yotti R, Bermejo J, Baares R. The heart in liver transplantation. J Hepatol: 2011; 54 4 810 822
36. Naritaka Y, Ogawa K, Shimakawa T., et al. Clinical experience of transjugular intrahepatic portosystemic shunt (TIPS) and its effects on systemic hemodynamics. Hepatogastroenterology: 2004; 51 59 1470 1472 (Pubitemid 38987508)
37. Ma Z, Lee SS. Cirrhotic cardiomyopathy: getting to the heart of the matter. Hepatology: 1996; 24 2 451 459 (Pubitemid 26260046)
38. Liu H, Gaskari SA, Lee SS. Cardiac and vascular changes in cirrhosis: pathogenic mechanisms. World J Gastroenterol: 2006; 12 6 837 842
39. Saba S, Janczewski AM, Baker LC., et al. Atrial contractile dysfunction, fibrosis, and arrhythmias in a mouse model of cardiomyopathy secondary to cardiac-specific overexpression of tumor necrosis factor-alpha. Am J Physiol Heart Circ Physiol: 2005; 289 4 H1456 H1467 (Pubitemid 41368987)
40. Myers RP, Lee SS. Cirrhotic cardiomyopathy and liver transplantation. Liver Transpl: 2000; 6 4, Suppl 1 S44 S52 (Pubitemid 30485867)
41. Pozzi M, Carugo S, Boari G., et al. Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites. Hepatology: 1997; 26 5 1131 1137 (Pubitemid 27509293)
42. Tsai MH, Peng YS, Chen YC., et al. Adrenal insufficiency in patients with cirrhosis, severe sepsis and septic shock. Hepatology: 2006; 43 4 673 681
43. Fernndez J, Escorsell A, Zabalza M., et al. Adrenal insufficiency in patients with cirrhosis and septic shock: effect of treatment with hydrocortisone on survival. Hepatology: 2006; 44 5 1288 1295 (Pubitemid 44748379)
44. Stadlbauer V, Wright GA, Banaji M., et al. Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in cirrhosis. Gastroenterology: 2008; 134 1 111 119
45. Gins A, Fernndez-Esparrach G, Monescillo A., et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology: 1996; 111 4 1002 1010 (Pubitemid 26327603)
46. Ruiz-del-Arbol L, Monescillo A, Jimenz W, Garcia-Plaza A, Arroyo V, Rods J. Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology: 1997; 113 2 579 586 (Pubitemid 27351786)
47. Follo A, Llovet JM, Navasa M., et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology: 1994; 20 6 1495 1501 (Pubitemid 24359062)
48. Sort P, Navasa M, Arroyo V., et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med: 1999; 341 6 403 409 (Pubitemid 29362513)
49. Fasolato S, Angeli P, Dallagnese L., et al. Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features. Hepatology: 2007; 45 1 223 229 (Pubitemid 46144382)
50. Terra C, Guevara M, Torre A., et al. Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score. Gastroenterology: 2005; 129 6 1944 1953 (Pubitemid 41772972)
51. Gins A, Escorsell A, Gins P., et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology: 1993; 105 1 229 236 (Pubitemid 23234041)
52. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology: 2000; 119 6 1637 1648 (Pubitemid 32198689)
53. Crdenas A, Gins P, Uriz J., et al. Renal failure after upper gastrointestinal bleeding in cirrhosis: incidence, clinical course, predictive factors, and short-term prognosis. Hepatology: 2001; 34 4 Pt 1 671 676 (Pubitemid 32927990)
54. Laffi G, La Villa G, Pinzani M, Marra F, Gentilini P. Arachidonic acid derivatives and renal function in liver cirrhosis. Semin Nephrol: 1997; 17 6 530 548 (Pubitemid 27465011)
55. Planas R, Montoliu S, Ballest B., et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol: 2006; 4 11 1385 1394
56. Wong LP, Blackley MP, Andreoni KA, Chin H, Falk RJ, Klemmer PJ. Survival of liver transplant candidates with acute renal failure receiving renal replacement therapy. Kidney Int: 2005; 68 1 362 370 (Pubitemid 43181396)
57. Montoliu S, Ballest B, Planas R., et al. Incidence and prognosis of different types of functional renal failure in cirrhotic patients with ascites. Clin Gastroenterol Hepatol: 2010; 8 7 616 622, quiz e80
58. Moreau R, Durand F, Poynard T., et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology: 2002; 122 4 923 930 (Pubitemid 34267275)
59. Salerno F, Gerbes A, Gins P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut: 2007; 56 9 1310 1318 (Pubitemid 47300435)
60. Arroyo V, Gins P, Gerbes AL., et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology: 1996; 23 1 164 176 (Pubitemid 26012105)
61. Watt K, Uhanova J, Minuk GY. Hepatorenal syndrome: diagnostic accuracy, clinical features, and outcome in a tertiary care center. Am J Gastroenterol: 2002; 97 8 2046 2050
62. Colle I, Durand F, Pessione F., et al. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis. J Gastroenterol Hepatol: 2002; 17 8 882 888
63. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology: 2004; 40 1 55 64 (Pubitemid 38868923)
64. Pron JM, Bureau C, Gonzalez L., et al. Treatment of hepatorenal syndrome as defined by the international ascites club by albumin and furosemide infusion according to the central venous pressure: a prospective pilot study. Am J Gastroenterol: 2005; 100 12 2702 2707
65. Gins P, Guevara M, Arroyo V, Rods J. Hepatorenal syndrome. Lancet: 2003; 362 9398 1819 1827 (Pubitemid 37494763)
66. Wong F, Nadim MK, Kellum JA., et al. Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut: 2011; 60 5 702 709
67. Salerno F, Cazzaniga M, Merli M., et al. Diagnosis, treatment and survival of patients with hepatorenal syndrome: a survey on daily medical practice. J Hepatol: 2011; 55 6 1241 1248
68. Levin A, Warnock DG, Mehta RL., et al. Acute Kidney Injury Network Working Group. Improving outcomes from acute kidney injury: report of an initiative. Am J Kidney Dis: 2007; 50 1 1 4 (Pubitemid 46962867)
69. Cholongitas E, Senzolo M, Patch D, Shaw S, O'Beirne J, Burroughs AK. Cirrhotics admitted to intensive care unit: the impact of acute renal failure on mortality. Eur J Gastroenterol Hepatol: 2009; 21 7 744 750
70. Jenq CC, Tsai MH, Tian YC., et al. RIFLE classification can predict short-term prognosis in critically ill cirrhotic patients. Intensive Care Med: 2007; 33 11 1921 1930
71. Davenport A, Cholongitas E, Xirouchakis E, Burroughs AK. Pitfalls in assessing renal function in patients with cirrhosispotential inequity for access to treatment of hepatorenal failure and liver transplantation. Nephrol Dial Transplant: 2011; 26 9 2735 2742
72. Slack A, Yeoman A, Wendon J. Renal dysfunction in chronic liver disease. Crit Care: 2010; 14 2 214
73. Wadei HM, Geiger XJ, Cortese C., et al. Kidney allocation to liver transplant candidates with renal failure of undetermined etiology: role of percutaneous renal biopsy. Am J Transplant: 2008; 8 12 2618 2626
74. Koppel MH, Coburn JW, Mims MM, Goldstein H, Boyle JD, Rubini ME. Transplantation of cadaveric kidneys from patients with hepatorenal syndrome. Evidence for the functional nature of renal failure in advanced liver disease. N Engl J Med: 1969; 280 25 1367 1371
75. Iwatsuki S, Popovtzer MM, Corman JL., et al. Recovery from "hepatorenal syndromeo" after orthotopic liver transplantation. N Engl J Med: 1973; 289 22 1155 1159
76. Marik PE, Wood K, Starzl TE. The course of type 1 hepato-renal syndrome post liver transplantation. Nephrol Dial Transplant: 2005; 21 2 478 482
77. Shusterman B, Mchedishvili G, Rosner MH. Outcomes for hepatorenal syndrome and acute kidney injury in patients undergoing liver transplantation: a single-center experience. Transplant Proc: 2007; 39 5 1496 1500 (Pubitemid 46907933)
78. Xu X, Ling Q, Zhang M., et al. Outcome of patients with hepatorenal syndrome type 1 after liver transplantation: Hangzhou experience. Transplantation: 2009; 87 10 1514 1519
79. Rice JP, Skagen C, Said A. Liver transplant outcomes for patients with hepatorenal syndrome treated with pretransplant vasoconstrictors and albumin. Transplantation: 2011; 91 10 1141 1147
80. Garca-Compean D, Blanc P, Larrey D., et al. Treatment of cirrhotic tense ascites with Dextran-40 versus albumin associated with large volume paracentesis: a randomized controlled trial. Ann Hepatol: 2002; 1 1 29 35
81. Quinlan GJ, Martin GS, Evans TW. Albumin: biochemical properties and therapeutic potential. Hepatology: 2005; 41 6 1211 1219 (Pubitemid 40770271)
82. Quinlan GJ, Mumby S, Martin GS, Bernard GR, Gutteridge JM, Evans TW. Albumin influences total plasma antioxidant capacity favorably in patients with acute lung injury. Crit Care Med: 2004; 32 3 755 759 (Pubitemid 38340073)
83. Fernndez J, Navasa M, Planas R., et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology: 2007; 133 3 818 824 (Pubitemid 47374144)
84. Arroyo V, Fernandez J. Pathophysiological basis of albumin use in cirrhosis. Ann Hepatol: 2011; 10 Suppl 1 S6 S14
85. Cade R, Wagemaker H, Vogel S., et al. Hepatorenal syndrome: studies of the effect of vascular volume and intraperitoneal pressure on renal and hepatic function. Am J Med: 1987; 82 3 427 438
86. Umgelter A, Reindl W, Franzen M, Lenhardt C, Huber W, Schmid RM. Renal resistive index and renal function before and after paracentesis in patients with hepatorenal syndrome and tense ascites. Intensive Care Med: 2009; 35 1 152 156
87. Umgelter A, Reindl W, Wagner KS., et al. Effects of plasma expansion with albumin and paracentesis on haemodynamics and kidney function in critically ill cirrhotic patients with tense ascites and hepatorenal syndrome: a prospective uncontrolled trial. Crit Care: 2008; 12 1 R4
88. Charlton MR, Wall WJ, Ojo AO., et al. International Liver Transplantation Society Expert Panel. Report of the first international liver transplantation society expert panel consensus conference on renal insufficiency in liver transplantation. Liver Transpl: 2009; 15 11 S1 S34
89. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol: 2010; 53 3 397 417
90. Ryckwaert F, Virsolvy A, Fort A., et al. Terlipressin, a provasopressin drug exhibits direct vasoconstrictor properties: consequences on heart perfusion and performance. Crit Care Med: 2009; 37 3 876 881
91. Arroyo V, Fernndez J. Management of hepatorenal syndrome in patients with cirrhosis. Nat Rev Nephrol: 2011; 7 9 517 526
92. Ortega R, Gins P, Uriz J., et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology: 2002; 36 4 Pt 1 941 948
93. Uriz J, Gins P, Crdenas A., et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol: 2000; 33 1 43 48 (Pubitemid 30418933)
94. Alessandria C, Venon WD, Marzano A, Barletti C, Fadda M, Rizzetto M. Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2. Eur J Gastroenterol Hepatol: 2002; 14 12 1363 1368 (Pubitemid 36054926)
95. Solanki P, Chawla A, Garg R, Gupta R, Jain M, Sarin SK. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol: 2003; 18 2 152 156 (Pubitemid 36349860)
96. Narahara Y, Kanazawa H, Taki Y., et al. Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis. J Gastroenterol Hepatol: 2009; 24 11 1791 1797
97. Nazar A, Pereira GH, Guevara M., et al. Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology: 2010; 51 1 219 226
98. Martn-Llah M, Ppin MN, Guevara M., et al. TAHRS Investigators. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology: 2008; 134 5 1352 1359 (Pubitemid 351626950)
99. Pron JM, Bureau C, Gonzalez L., et al. Treatment of hepatorenal syndrome as defined by the international ascites club by albumin and furosemide infusion according to the central venous pressure: a prospective pilot study. Am J Gastroenterol: 2005; 100 12 2702 2707
100. Fernndez J, Monteagudo J, Bargallo X., et al. A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology: 2005; 42 3 627 634 (Pubitemid 41233655)
101. Sanyal AJ, Boyer T, Garcia-Tsao G., et al. Terlipressin Study Group. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology: 2008; 134 5 1360 1368 (Pubitemid 351615358)
102. Sagi SV, Mittal S, Kasturi KS, Sood GK. Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol: 2010; 25 5 880 885
103. Duvoux C, Zanditenas D, Hzode C., et al. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology: 2002; 36 2 374 380 (Pubitemid 34810356)
104. Pomier-Layrargues G, Paquin SC, Hassoun Z, Lafortune M, Tran A. Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study. Hepatology: 2003; 38 1 238 243 (Pubitemid 36775816)
105. Angeli P, Volpin R, Piovan D., et al. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites. Hepatology: 1998; 28 4 937 943 (Pubitemid 28450253)
106. Singh V, Dhungana SP, Singh B., et al. Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study. J Hepatol: 2011; Jul 13. [Epub ahead of print]
107. Angeli P, Volpin R, Gerunda G., et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology: 1999; 29 6 1690 1697 (Pubitemid 29247040)
108. Skagen C, Einstein M, Lucey MR, Said A. Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome. J Clin Gastroenterol: 2009; 43 7 680 685
109. Kiser TH, Fish DN, Obritsch MD, Jung R, MacLaren R, Parikh CR. Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study. Nephrol Dial Transplant: 2005; 20 9 1813 1820 (Pubitemid 41222593)
110. Dobre M, Demirjian S, Sehgal AR, Navaneethan SD. Terlipressin in hepatorenal syndrome: a systematic review and meta-analysis. Int Urol Nephrol: 2011; 43 1 175 184
111. Gluud LL, Christensen K, Christensen E, Krag A. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology: 2010; 51 2 576 584
112. Caraceni P, Santi L, Mirici F., et al. Long-term treatment of hepatorenal syndrome as a bridge to liver transplantation. Dig Liver Dis: 2011; 43 3 242 245
113. Jalan R, Redhead DN, Thomas HW., et al. Mechanisms of changes in renal handling of sodium following transjugular intrahepatic portal systemic stent-shunt (TIPSS). Eur J Gastroenterol Hepatol: 1996; 8 11 1111 1116 (Pubitemid 26383871)
114. Gerbes AL, Gülberg V, Waggershauser T, Holl J, Reiser M. Renal effects of transjugular intrahepatic portosystemic shunt in cirrhosis: comparison of patients with ascites, with refractory ascites, or without ascites. Hepatology: 1998; 28 3 683 688 (Pubitemid 28405416)
115. Guevara M, Gins P, Bandi JC., et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology: 1998; 28 2 416 422 (Pubitemid 28363668)
116. Brensing KA, Textor J, Perz J., et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut: 2000; 47 2 288 295 (Pubitemid 30489776)
117. Rössle M, Gerbes AL. TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update. Gut: 2010; 59 7 988 1000
118. Testino G, Ferro C, Sumberaz A., et al. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation. Hepatogastroenterology: 2003; 50 54 1753 1755 (Pubitemid 37467926)
119. Guerrini GP, Pleguezuelo M, Maimone S., et al. Impact of tips preliver transplantation for the outcome posttransplantation. Am J Transplant: 2009; 9 1 192 200
120. Wilkinson SP, Weston MJ, Parsons V, Williams R. Dialysis in the treatment of renal failure in patients with liver disease. Clin Nephrol: 1977; 8 1 287 292 (Pubitemid 8145514)
121. Ellis D, Avner ED. Renal failure and dialysis therapy in children with hepatic failure in the perioperative period of orthotopic liver transplantation. Clin Nephrol: 1986; 25 6 295 303 (Pubitemid 16083032)
122. Keller F, Heinze H, Jochimsen F, Passfall J, Schuppan D, Büttner P. Risk factors and outcome of 107 patients with decompensated liver disease and acute renal failure (including 26 patients with hepatorenal syndrome): the role of hemodialysis. Ren Fail: 1995; 17 2 135 146
123. Davenport A. Renal replacement therapy in the patient with acute brain injury. Am J Kidney Dis: 2001; 37 3 457 466 (Pubitemid 32195283)
124. Davenport A, Will EJ, Davison AM. Effect of renal replacement therapy on patients with combined acute renal and fulminant hepatic failure. Kidney Int Suppl: 1993; 41 S245 S251
125. Davenport A, Will EJ, Davidson AM. Improved cardiovascular stability during continuous modes of renal replacement therapy in critically ill patients with acute hepatic and renal failure. Crit Care Med: 1993; 21 3 328 338 (Pubitemid 23097026)
126. Detry O, Arkadopoulos N, Ting P., et al. Intracranial pressure during liver transplantation for fulminant hepatic failure. Transplantation: 1999; 67 5 767 770 (Pubitemid 29161724)
127. Witzke O, Baumann M, Patschan D., et al. Which patients benefit from hemodialysis therapy in hepatorenal syndrome? J Gastroenterol Hepatol: 2004; 19 12 1369 1373 (Pubitemid 40052855)
128. Gonwa TA, Mai ML, Melton LB., et al. Renal replacement therapy and orthotopic liver transplantation: the role of continuous veno-venous hemodialysis. Transplantation: 2001; 71 10 1424 1428 (Pubitemid 32507116)
129. Bellomo R, Teede H, Boyce N. Anticoagulant regimens in acute continuous hemodiafiltration: a comparative study. Intensive Care Med: 1993; 19 6 329 332 (Pubitemid 23284795)
130. Biancofiore G, Esposito M, Bindi L., et al. Regional filter heparinization for continuous veno-venous hemofiltration in liver transplant recipients. Minerva Anestesiol: 2003; 69 6 527 534, 534-538
131. Liu KD, Himmelfarb J, Paganini E., et al. Timing of initiation of dialysis in critically ill patients with acute kidney injury. Clin J Am Soc Nephrol: 2006; 1 5 915 919
132. Payen D, de Pont AC, Sakr Y, Spies C, Reinhart K, Vincent JL.; Sepsis Occurrence in Acutely Ill Patients (SOAP) Investigators. A positive fluid balance is associated with a worse outcome in patients with acute renal failure. Crit Care: 2008; 12 3 R74
133. Palevsky PM, Zhang JH, O'Connor TZ., et al. VA/NIH Acute Renal Failure Trial Network. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med: 2008; 359 1 7 20 (Pubitemid 351931092)
134. Bellomo R, Cass A, Cole L., et al. RENAL Replacement Therapy Study Investigators. Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med: 2009; 361 17 1627 1638
135. Piccinni P, Dan M, Barbacini S., et al. Early isovolaemic haemofiltration in oliguric patients with septic shock. Intensive Care Med: 2006; 32 1 80 86 (Pubitemid 43039380)
136. Mitzner SR, Stange J, Klammt S., et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl: 2000; 6 3 277 286 (Pubitemid 30317221)
137. Faubion WA, Guicciardi ME, Miyoshi H., et al. Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. J Clin Invest: 1999; 103 1 137 145 (Pubitemid 29031172)
138. Bomzon A, Holt S, Moore K. Bile acids, oxidative stress, and renal function in biliary obstruction. Semin Nephrol: 1997; 17 6 549 562 (Pubitemid 27465012)
139. Mitzner SR, Klammt S, Peszynski P., et al. Improvement of multiple organ functions in hepatorenal syndrome during albumin dialysis with the molecular adsorbent recirculating system. Ther Apher: 2001; 5 5 417 422 (Pubitemid 34033340)
140. Oppert M, Rademacher S, Petrasch K, Jörres A. Extracorporeal liver support therapy with Prometheus in patients with liver failure in the intensive care unit. Ther Apher Dial: 2009; 13 5 426 430
141. Townsend DR, Bagshaw SM, Jacka MJ, Bigam D, Cave D, Gibney RT. Intraoperative renal support during liver transplantation. Liver Transpl: 2009; 15 1 73 78
142. Navasa M, Feu F, Garca-Pagn JC., et al. Hemodynamic and humoral changes after liver transplantation in patients with cirrhosis. Hepatology: 1993; 17 3 355 360 (Pubitemid 23072807)
143. Piscaglia F, Zironi G, Gaiani S., et al. Systemic and splanchnic hemodynamic changes after liver transplantation for cirrhosis: a long-term prospective study. Hepatology: 1999; 30 1 58 64 (Pubitemid 29300569)
144. Ruiz R, Kunitake H, Wilkinson AH., et al. Long-term analysis of combined liver and kidney transplantation at a single center. Arch Surg: 2006; 141 8 735 741, discussion 741-742 (Pubitemid 44268509)
145. Jeyarajah DR, Gonwa TA, McBride M., et al. Hepatorenal syndrome: combined liver kidney transplants versus isolated liver transplant. Transplantation: 1997; 64 12 1760 1765 (Pubitemid 28041715)
146. Eason JD, Gonwa TA, Davis CL, Sung RS, Gerber D, Bloom RD. Proceedings of consensus conference on simultaneous liver kidney transplantation (SLK). Am J Transplant: 2008; 8 11 2243 2251
147. Pawarode A, Fine DM, Thuluvath PJ. Independent risk factors and natural history of renal dysfunction in liver transplant recipients. Liver Transpl: 2003; 9 7 741 747 (Pubitemid 36874464)
148. Gonwa TA, Mai ML, Melton LB., et al. End-stage renal disease (ESRD) after
149. Lee JP, Heo NJ, Joo KW., et al. Risk factors for consequent kidney impairment and differential impact of liver transplantation on renal function. Nephrol Dial Transplant: 2010; 25 8 2772 2785
150. Ruiz R, Barri YM, Jennings LW., et al. Hepatorenal syndrome: a proposal for kidney after liver transplantation (KALT). Liver Transpl: 2007; 13 6 838 843 (Pubitemid 46947848)
151. Gonwa TA, McBride MA, Mai ML, Wadei HM. Kidney transplantation after previous liver transplantation: analysis of the organ procurement transplant network database. Transplantation: 2011; 92 1 31 35
152. Gonwa TA, Klintmalm GB, Levy M, Jennings LS, Goldstein RM, Husberg BS. Impact of pretransplant renal function on survival after liver transplantation. Transplantation: 1995; 59 3 361 365
153. Restuccia T, Ortega R, Guevara M., et al. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome: a case-control study. J Hepatol: 2004; 40 1 140 146 (Pubitemid 38064723)
154. Arroyo V, Fernandez J, Gins P. Pathogenesis and treatment of hepatorenal syndrome. Semin Liver Dis: 2008; 28 1 81 95 (Pubitemid 351326535)
155. Davenport A. Management of acute kidney injury in liver disease. Contrib Nephrol: 2010; 165 197 205